- Home
- SNTI vs FMY Comparison
SNTI vs FMY Comparison
Compare SNTI & FMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- FMY
- Stock Information
- Founded
- SNTI 2016
- FMY 2005
- Country
- SNTI United States
- FMY United States
- Employees
- SNTI N/A
- FMY N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- FMY Finance/Investors Services
- Sector
- SNTI Health Care
- FMY Finance
- Exchange
- SNTI Nasdaq
- FMY Nasdaq
- Market Cap
- SNTI 53.6M
- FMY 51.6M
- IPO Year
- SNTI N/A
- FMY N/A
- Fundamental
- Price
- SNTI $2.15
- FMY $12.00
- Analyst Decision
- SNTI Strong Buy
- FMY
- Analyst Count
- SNTI 3
- FMY 0
- Target Price
- SNTI $9.67
- FMY N/A
- AVG Volume (30 Days)
- SNTI 327.7K
- FMY 10.1K
- Earning Date
- SNTI 11-13-2025
- FMY 01-01-0001
- Dividend Yield
- SNTI N/A
- FMY 6.98%
- EPS Growth
- SNTI N/A
- FMY N/A
- EPS
- SNTI N/A
- FMY N/A
- Revenue
- SNTI N/A
- FMY N/A
- Revenue This Year
- SNTI N/A
- FMY N/A
- Revenue Next Year
- SNTI $150.00
- FMY N/A
- P/E Ratio
- SNTI N/A
- FMY N/A
- Revenue Growth
- SNTI N/A
- FMY N/A
- 52 Week Low
- SNTI $1.26
- FMY $10.71
- 52 Week High
- SNTI $16.94
- FMY $12.17
- Technical
- Relative Strength Index (RSI)
- SNTI 62.17
- FMY 37.01
- Support Level
- SNTI $1.92
- FMY $12.10
- Resistance Level
- SNTI $2.29
- FMY $12.16
- Average True Range (ATR)
- SNTI 0.25
- FMY 0.10
- MACD
- SNTI 0.01
- FMY -0.02
- Stochastic Oscillator
- SNTI 55.06
- FMY 11.11
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.